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Abstract
Background: A landmark randomised trial of male circumcision (MC) in Orange Farm, South Africa
recently showed a large and significant reduction in risk of HIV infection, reporting MC effectiveness of
61% (95% CI: 34%–77%). Additionally, two further randomised trials of MC in Kisumu, Kenya and Rakai,
Uganda were recently stopped early to report 53% and 48% effectiveness, respectively. Since MC may
protect against both HIV and certain sexually transmitted infections (STI), which are themselves cofactors
of HIV infection, an important question is the extent to which this estimated effectiveness against HIV is
mediated by the protective effect of circumcision against STI. The answer lies in the trial data if the
appropriate statistical analyses can be identified to estimate the separate efficacies against HIV and STI,
which combine to determine overall effectiveness.
Objectives and Methods: Focusing on the MC trial in Kisumu, we used a stochastic prevention trial
simulator (1) to determine whether statistical analyses can validly estimate efficacy, (2) to determine
whether MC efficacy against STI alone can produce large effectiveness against HIV and (3) to estimate the
fraction of all HIV infections prevented that are attributable to efficacy against STI when both efficacies
combine.
Results: Valid estimation of separate efficacies against HIV and STI as well as MC effectiveness is feasible
with available STI and HIV trial data, under Kisumu trial conditions. Under our parameter assumptions,
high overall effectiveness of MC against HIV was observed only with a high MC efficacy against HIV and
was not possible on the basis of MC efficacy against STI alone. The fraction of all HIV infections prevented
which were attributable to MC efficacy against STI was small, except when efficacy of MC specifically
against HIV was very low. In the three MC trials which reported between 48% and 61% effectiveness
(combining STI and HIV efficacies), the fraction of HIV infections prevented in circumcised males which
were attributable to STI was unlikely to be more than 10% to 20%.
Conclusion: Estimation of efficacy, attributable fraction and effectiveness leads to improved
understanding of trial results, gives trial results greater external validity and is essential to determine the
broader public health impact of circumcision to men and women.
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The role of male circumcision (MC) in protecting against
HIV infection in sub-Saharan Africa has been controver-
sial since the beginning of the HIV epidemic. This is
because evidence derived from observational studies is
prone to bias due to confounding risk factors and because
MC as a HIV prevention strategy can be seen as unethical
[1-3]. There is mounting epidemiological evidence and
plausible biological explanation to indicate that MC can
protect against HIV both directly and indirectly [4-11].
Risk due to abrasions suffered by foreskin in uncircum-
cised men, inflammatory conditions under the foreskin
and high concentrations of Langerhans cells which are tar-
gets for HIV infection can be directly minimised by MC
[4,5]. Evidence also exists for an association between MC
and reduced risk of infection with certain sexually trans-
mitted infections (STI) such as chancroid, syphilis, gonor-
rhoea and HSV [6-12]. Because these STIs are co-factors of
HIV transmission [13], indirect protection against HIV,
mediated by the benefit of MC against STIs, is also possi-
ble.
The role of male circumcision as a HIV prevention tool is
now supported by a landmark randomised trial that
showed a large and significant effectiveness against HIV
(61%; 95% CI: 34%–77%) among a sample of adult men
in Orange Farm, South Africa [14]. Recently, two addi-
tional independent randomised MC trials in Kisumu,
Kenya [15,16] and Rakai, Uganda [17] were stopped early
upon finding significant effectiveness against HIV of 53%
and 48%, respectively [18]. The magnitude of these esti-
mates is in line with meta-analyses of observational stud-
ies [8,19-22]. Now, further efforts are being made to better
understand trial results and their implications for public
health [23,24]. In particular, the role STIs played in the
overall effectiveness of MC against HIV in the three trials
needs to be better understood as does the applicability of
the trial findings to other settings with different HIV and
STI epidemiology. This cannot be ascertained from MC
trials alone because they, like most HIV prevention trials,
have primary objective to demonstrate the overall reduc-
tion in the risk of HIV infection, called effectiveness.
While estimation of effectiveness addresses the primary
objective of the trial by comparing infection rates between
circumcised men and controls, it does not specifically
measure the separate effects of MC against HIV and other
STIs. Thus, a clinical trial of MC conducted in a setting
with high levels of STI may give rise to an important dif-
ference in HIV infection between trial arms, pointing to a
positive overall effectiveness without pinpointing why
this result is achieved. Without this clarity on a positive
effectiveness, it is difficult to know to which extent the
overall HIV risk reduction is due to the direct versus indi-
rect protective effect of MC against HIV.
These questions can be answered if the appropriate statis-
tical analyses can be identified. This involves estimation
of the efficacies of MC against HIV and STI separately, as
well as the usual estimation of overall effectiveness from
randomised trials. These efficacy and effectiveness esti-
mates can then be combined to deduce the fraction of HIV
infections prevented by MC which are attributable to STI.
In this paper we use a prevention trial simulator of cir-
cumcision, using data from the Kisumu MC trial, where
HIV and STI both circulate (1) to demonstrate which sta-
tistical analyses validly estimate efficacy against HIV and
STI; (2) to examine whether the efficacy of MC on STI
alone can result in a large overall estimates of HIV effec-
tiveness a in randomised trial when MC does not have a
direct protective effect against HIV; and (3) to examine
when both efficacies combine, what is the attributable
fraction of all HIV infections prevented by efficacy against
STI in a MC trial. The results of our modelling study will
facilitate and improve interpretation of the results of the
three MC trials. In turn, this will eventually lead to better
understanding of the population-level effectiveness and
cost-effectiveness of circumcision in settings with different
STI and HIV epidemiology.
Analysis
Definitions of efficacy, effectiveness and attributable 
fraction
It is crucial to distinguish between efficacy and effective-
ness as they are used in phase 3 HIV prevention trials.
Effectiveness, denoted F, estimates the total difference in
HIV infection rates between trial arms. In a phase 3 trial,
the estimated effectiveness will depend on several factors.
These include the direct reduction in female-to-male HIV
transmission probability due to circumcision, the direct
reduction in female-to-male STI transmission, prevalence
of STI in trial participants and their partners, and strength
of the HIV-STI epidemiological interaction. Since STI
prevalence can change with time in trial participants,
effectiveness estimates can also depend on the duration of
follow-up. Thus, effectiveness is an estimate of the aggre-
gate effects of several factors whose interpretation is lim-
ited to the trial context in which it is estimated and is a
time-dependent quantity. We use the term effectiveness in
its clinical trial sense which is more limited than its epide-
miological sense where it would represent impact of MC
in a general population. In particular, the effectiveness
estimated in a clinical trial says nothing about the herd
effect of MC benefiting females.
Efficacy against HIV, denoted EH, represents the direct
reduction in female-to-male HIV transmission probability
due to circumcision, just one of the factors determining
effectiveness. Similarly, efficacy against STI, denoted ES,
represents the reduction in female-to-male STI transmis-Page 2 of 16
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description of the effect of circumcision which is inde-
pendent of setting and time and has a biological interpre-
tation which is more generalisable and simpler to
interpret than effectiveness.
We also define attributable fraction, denoted AF, as the
proportion of all HIV infections prevented that are medi-
ated by MC efficacy against STI. This quantity describes
how much of the overall effectiveness of MC against HIV
is due to the indirect effect mediated by MC efficacy
against STI. The AF can be approximated using estimates
of F and EH (see later).
Clinical trial simulator
Dynamic stochastic models simulating trial designs are
well suited to study this type of question and have been
used successfully in the past to evaluate the quality of epi-
demiological studies on the STI and HIV interaction and
to validate statistical analyses for HIV vaccine trials [25-
29]. Our stochastic compartmental model (see Endnote)
simulates transmission of HIV and one STI in a heterosex-
ual population in which a clinical trial is embedded and
is based on previous models that we have used [27,29].
Individuals in the population are heterogenous with
respect to sexual activity stratified into classes with differ-
ent rates of sexual partner acquisition. The STI has been
modelled simplistically with two compartments repre-
senting infected or not infected. The STI in the model
should be thought of as 'generic', rather than representing
any one specific STI. HIV infection has been modelled
with 5 states representing susceptibles, early- and latent-
infection, pre-AIDS and AIDS. Flow of individuals
between states is based on flow rates determined from
specified parameters or from force of infection equations.
Flow rates are instantly updated following each event.
Flow of individuals through different HIV states is unidi-
rectional, whereas individuals can recover from STI and be
reinfected. Infection rates for different individuals in the
population depend on their sexual activity, their HIV or
STI infection status, HIV and STI prevalence in their part-
ners, and strength of HIV-STI interaction as cofactors of
transmission and circumcision status. Individuals are
recruited from the general population for the clinical trial
and are followed-up recording the times of their infection
events.
The model generates simulated trial data which are then
analysed to estimate efficacy against HIV, STI and overall
effectiveness against HIV. The efficacy estimates are valid
when they agree with the true values embedded in the
simulation.
Model parameters and description of Kisumu circumcision 
study
The base-case model parameter values were selected
according to trial design parameters from the UNIM cir-
cumcision trial in Kisumu District of Kenya [15,16], were
estimated from the trial's baseline and follow-up data, or
were based on relevant published literature. Parameter
values and references are given in Table 1.
The Kenyan circumcision study is an unblinded rand-
omized controlled trial which began recruiting uncircum-
cised, HIV seronegative Luo men aged 18–24 years in
February 2002. The Luo are a homogenous traditionally
non-circumcising ethnic group in western Kenya. The pri-
mary objective is the determination of reduction in inci-
dence of HIV infection, interpreted as effectiveness.
Estimation of reduction in incidence of STI is a secondary
objective. A total of 2784 participants are equally rand-
omized to each arm of the trial and followed for 24
months. The estimated annual HIV infection rate in the
control group is 2.5% yr-1 and loss to follow-up is 15%.
Given these trial parameters, 63 infection events would be
expected in the control arm of the trial. This implies a 70%
probability (power) of declaring an efficacy better than
zero when the true effectiveness is 40%, or 90% power
when true effectiveness is 50%. HIV prevalence in Luo
men at screening was 7.4% and HIV incidence is esti-
mated at 2.5%. The Kenya Demographic and Health Sur-
vey (DHS) [30] also reports HIV prevalence : Luo men
aged 15–49 were reported to be 17.5% positive for HIV
and uncircumcised Kenyan males aged 15–54 were 12.6%
positive for HIV. STI prevalence in trial participants at
enrolment was 2.0% urine positive for Neisseria gonor-
rhoea, 2.6% urine positive for Trachoma vaginalis (in
pouch culture test), 2.8% rapid plasma reagent positive
for syphilis, 5.0% urine positive for Chlamydia trachom-
atis and 25.0% antibody positive for HSV. The Kenya DHS
also indicates 7.6% of males in Nyanza self-reported STI
infection, abnormal genital discharge or ulcerative sores
in the last year [30].
Model parameters for sample size, follow-up duration
and randomisation ratio were chosen according to the
trial's design characteristics. The size of the population
hosting the trial was assumed to be much larger than the
sample size of the study. The sexual behaviour parameters
(i.e. distribution of the sexual activity classes and the rate
of sexual partner acquisition) in the model were chosen to
reproduce trial data and Kenyan DHS data on HIV preva-
lence, HIV incidence and STI prevalence. This parameter
selection also ensured the simulated power, as deter-
mined by number of expected endpoints, were closely
matched to the trial's actual power. Under base-case
parameter values, the model's HIV prevalence in the gen-
eral population averaged 18.0% over the time of the trial,Page 3 of 16
(page number not for citation purposes)
Emerging Themes in Epidemiology 2006, 3:19 http://www.ete-online.com/content/3/1/19HIV incidence rate in the simulated trials was 2.5% per
year in control subjects, and STI prevalence in simulations
averaged 8.2% in controls. Over the trial period HIV and
STI prevalence remained unchanged. The simulated trials
produced an average of 66 HIV infection events in the
control arm.
Remaining parameters for HIV and STI transmission
probabilities, duration of the different HIV states and
duration of STI infection were estimated based on other
published studies. In particular, the strength of interaction
modelled between HIV and STI under base-case assump-
tions is assumed to be medium; presence of STI in the
HIV-infected sexual partner increases the per partnership
probability of HIV transmission by a factor of 4 (α1 = 4),
while STI in the HIV-susceptible increases HIV transmis-
sion by a factor of 3 (α1 = 3). This compares with a review
on the increased susceptibility to HIV due to STIs [13]
where relative risk in men was 3.1 for all STIs, 4.4 for gen-
ital ulcer disease, 2.7 for herpes, 2.5 for syphilis, 3.9 for
gonorrhoea and 0.8 for chlamydia. In our simulations,
the STI had an average duration of infection of 6 months.
Table 1: Model Parameters. Base-case parameter values used in model simulations and base-case outputs for HIV and STI prevalence 
and incidence are given. Upper and lower limits for parameters varied in sensitivity analyses are also given.
Symbol Description of epidemiological parameters Parameter value References
γ1,...,γ3 Rate of progression between 3 stages of HIV infection. Duration of 
stage 1 is 1/γ1 = 4.4 months, stage 2 is 1/γ2 = 6.5 yrs, stage 3 is 1/γ3 = 2 
yrs.
γ1 = 2.75γ2 = 0.154γ3 = 0.5
[27,34-41]
Per partnership probability of transmission of HIV from individual of sex k*, sexual activity class j and infection phase p (p = 
1,...,3) to partner of opposite sex k and class i. Values given are transmission probabilities for females (k* = 1) of low activity 
class (j = 1,2 = lowf) or high activity class (j = 3,...,6 = highf) to males of low activity class (i = 1,2 = lowm) or high activity class (i 
= 3,...,6 = highm). Transmission probabilities for male to female are double of these below. Under sensitivity analyses, values 
were multiplied by a factor of 0.5, 2.0 or 4.0.
 = 0.08  = 0.0032
 = 0.043  = 0.0017
 = 0.025  = 0.001
 = 0.025  = 0.001
 = 0.051
 = 0.026
 = 0.0071
 = 0.0071
[27,34,36-28,42-44]
σk,i Recovery rate of STI infection. Duration of infection is 1/σk,i = 6 months 
for all sexes k and activity classes i.
σk,i = 2.0. Under sensitivity analyses σk,i = 3.0, 0.75. [45-47]
ξk,j,i Per partnership probability of transmission of STI from infected 
individual of sex k and sexual activity class j to partner of opposite sex 
k* and class i.
ξk,j,i = 0.15 for all k,i,j [45-47]
A1, a2 Enhancement of HIV transmission given STI infection. a1 is the relative 
risk (multiplicative factor) for increased susceptibility to HIV given STI 
infection in the partner. a2 is the relative risk of increased susceptibility 
to HIV given STI infection in self.
a1 = 4
a2 = 3
Under sensitivity analysis a1 = 2 & a2 = 2 and a1 = 6 & 
a2 = 6.
[13]
α Mortality rate due to AIDS
 = 1 year
[39-41]
mk,i Annual rate of sexual partner change. mk,i is the number of new sexual 
partners per year for person of sex k and sexual activity class i.
mk = 1,i = 1...6 = 1.0 3.5 5 10 50 75
mk = 2,i = 1...6 = 1.5 5.0 10 15 20 25
Assumed
ppk,i Percentage of population by activity class i for class k at start of HIV 
epidemic.
ppk = 1, = 1...6 = 55 20 10 10 2.5 2.5
ppk = 2, = 1...6 = 50 30 5 5 5 5
Assumed
μ Rate of departure from sexually active population. Lifetime of sexual 
activity is 1/μ = 35 yrs.
μ = 0.02857 Assumed
Population Size of population hosting clinical trial. 200 000 Assumed
Sample size Number of individuals recruited to clinical trial (controls + 
circumcised).
2 750 with 1:1 randomization [15,16]
Recruitment class Trial participants are recruited from sex k = 2 and sexual activity classes 
i = 1,...,3 in same proportions as in ppk,i
Follow-up Maximum person-time contributed per individual. 2 years [15,16]
Incidence- HIV Average incidence rate of HIV in control group over course of clinical 
trial.
2.5%/year (This is a model output) [15,16]
Incidence – STI Average incidence rate of STI in control group over course 
of clinical trial.
22.0%/year (This is a model output)
Prevalence – HIV Prevalence of HIV in general population. 18% during course of trial (This is a model 
output)
[15,16,30]
Prevalence – STI Prevalence of STI in control group 8.2 %. Under sensitivity analysis, prevalence 
is 1.8% and 19.0%. (This is a model output)
[15,16,30]
EH Efficacy against HIV due to circumcision. EH = 0%, 10%, 20%, ..., 70% Assumed
ES Efficacy against STI due to circumcision ES = 0% to 80% Assumed
β
k j i
p
∗ , ,
β11, ,lowf lowm β12, ,lowf lowm
β11, ,lowf highm β12, ,lowf highm
β11, ,highf lowm β12, ,highf lowm
β11, ,highf highm β12, ,highf highm
β13, ,lowf lowm
β13, ,lowf highm
β13, ,highf lowm
β13, ,highf highm
1
αPage 4 of 16
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We denote estimated values of EH, ES, F and AF by H,
S,  and  to distinguish them from their true values.
Trial data generated by the model for each individual
include the exact HIV infection time or right-censored
times in case of loss to follow-up or trial closure, STI infec-
tion times and recovery times, and randomisation group.
Estimation of EH is based on comparison of HIV infection
times between trial arms where individuals' follow-up
times are stratified into STI-positive and STI-negative
intervals using exact STI infection and recovery times.
Given the main endpoint is time to HIV infection where
STI status is changing during the follow-up period and
that multiple STI events are possible per individual, the
Anderson-Gill counting process (a generalization of Cox
proportional hazard models) with robust variance esti-
mates is the most suitable method for estimation of EH
[31,32]. The Anderson-Gill counting process is also the
appropriate analysis for estimating ES. Estimation of F is
based on comparison of HIV infection times between con-
trol and treated arms without stratification for STI infec-
tion. The proportion of HIV infections prevented which
are attributable to MC efficacy against STI is approximated
by . This approximation is valid under low
incidence of HIV infection and low STI prevalence, as
under the Kisumu base-case assumptions. Analyses were
implemented with SAS version 8.1 [33].
Simulations and sensitivity analysis
Values for EH, modelled as a reduction in susceptibility
upon exposure varied between 0% and 70%. Similarly,
values for ES between 0% to 80% were explored. Low ES
(~0–20%) reflects the efficacy of MC on Chlamydia and
HSV while high ES (~60–80%) reflects efficacy against
chancroid and syphilis [8]. Forty scenarios of efficacy for
EH and ES were simulated 100 times and analysed individ-
ually, giving 4000 simulated trials under base-case param-
eter values. The first objective was addressed by
comparing the estimated H against the true value for EH
embedded in the 4,000 simulated trials. The second
objective was addressed by examining the 5 scenarios
where true EH = 0%. The third objective was addressed by
the examining attributable fraction AF in the 4,000 simu-
lated trials.
Further simulations to test the robustness of our conclu-
sions were performed by univariate and bivariate sensitiv-
ity analyses (see Table 1). Under univariate analyses we
varied parameters which influence STI prevalence and the
role of STI in HIV transmission. Thus, we considered short
(4 months) and long (1.3 years) duration of sexually
transmitted infection resulting in STI prevalences of 1.8%
and 19.0%, a higher strength of HIV-STI interaction (α1 =
6, α2 = 6) and a weaker HIV-STI interaction (α1 = 2, α2 =
2). Bivariate sensitivity analyses were additionally per-
formed by varying the above parameters with compensat-
ing changes in HIV transmission probabilities in order to
maintain annual HIV incidence in the trial constant at
2.5%, thus maintaining the power of the simulated study
at a realistic level.
Additionally, for the first objective, the validity of efficacy
estimation under 'inexact data' was assessed using inter-
val-censored data assuming HIV and STI screening at 4, 6
and 8 months, corresponding to six, four and three testing
times per 2 year follow-up. We also estimate efficacy con-
trolling STI as a dichotomous variable representing 'STI
ever' during follow-up.
Results
Validity of H and S estimates
In order to understand the relative importance of STIs in
the prevention of HIV infections in phase 3 circumcision
trials, we must be sure that the efficacy estimator of EH is
statistically valid (i.e. unbiased). Table 2 gives the esti-
mated H where true EH varies from 0–70% and true ES
varies from 0–80%. The estimates of EH reflect the true
value embedded in each simulation, given that the
median H estimate over 100 simulations falls within ±
2.9% of the true value in all scenarios. Furthermore the
H estimates and their confidence limits were unchanged
by efficacy against STI (reading down columns), contrary
to the corresponding effectiveness estimates  (Table 3).
The effectiveness estimates generally overestimated effi-
cacy by up to 13%, indicating the need to control for STI
appropriately in statistical analyses.
However, when MC has no efficacy against STI (first row
in Tables 2 &3), both H and  both validly reflect the
true circumcision efficacy against HIV embedded in the
simulation. The fact that H and  agree is evidence that
the crude difference in HIV infection rates between trial
arms is due only to the efficacy against HIV and there is no
additional benefit in terms of protection against STI. This
Eˆ
Eˆ Fˆ AF?
AF
F E
F
H?
=
−
ˆ ˆ
ˆ
Eˆ
Eˆ Eˆ
Eˆ
Eˆ
Eˆ
Fˆ
Eˆ Fˆ
Eˆ FˆPage 5 of 16
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efficacy (with slight negative bias) against STI.
Table 4 gives S estimates under different true ES and true
EH. The true ES is slightly underestimated. This arises
because of unbalanced censoring between trial arms.
When analysing STI infection endpoints, censoring arises
due to HIV infections which are linked to trial arm. In
other words, when there is positive efficacy against HIV or
an STI-cofactor, more censoring due to HIV infections will
occur in the control arm compared to the circumcision
arm, particularly reducing the person-time of higher risk
uncircumcised men in the trial. Interestingly, the magni-
tude of the underestimation increases with EH, but never
by more than 5%, under the conditions explored. Further-
more, given the greater incidence of STI infections com-
pared to HIV, chances for detecting even small efficacies
against STI, though negatively biased, will be good as
reflected by the tight confidence intervals for ES in our
simulated trials.
Under trial conditions, the exact STI and HIV infection
times are unlikely to be available. Therefore we consid-
ered analyses based on data where HIV and STI infection
times are interval-censored by 4, 6 or 8-month visit inter-
vals. The efficacy estimates were typically between the cor-
responding values in Tables 2 and 3. Note however that
the interval censored results frequently lie closer to the
H estimates based on exact time than to  estimates.
Since H estimates made with interval censored data dif-
fered by ± 3% relative to exact time data, little statistical
validity is in fact lost. Similarly, little validity was lost in
estimation of ES using interval censored data compared to
exact data. However, when STI control was attempted
Eˆ
Eˆ
Eˆ Fˆ
Eˆ
Table 2: Estimates of efficacy against HIV ( H) and confidence intervals for simulated Kisumu MC trials under different levels of true 
efficacy against HIV (EH) and STI (ES) and base-case assumptions. Values for H are the median values obtained over 100 repetitions 
while values in brackets are the median values for upper and lower limits of 95% confidence intervals for EH.
Estimated H and 
95% CI
Efficacy against HIV (true EH)
0% 10% 20% 30% 40% 50% 60% 70%
Efficacy 
against STI 
(true ES)
0% -1.4 (-43.2,27.6) 9.3 (-28.2,36.9) 21.0 (-13.5,43.7) 29.0 (-3.3,51.3) 37.6 (7.8,58.0) 49.6 (22.8,66.7) 58.5 (34.9,73.9) 69.6 (49.9,81.6)
20% -0.6 (-39.6,29.8) 9.9 (-27.6,35.9) 20.2 (-16.6,44.2) 32.2 (1.8,53.5) 39.1 (9.9,58.6) 51.6 (25.3,68.3) 59.8 (37.6,74.5) 70.7 (52.5,83.2)
40% 0.5 (-45.1,29.5) 10.3 (-23.9,39.9) 19.9 (-16.1,44.6) 29.2 (-5.0,51.7) 37.3 (7.0,57.9) 48.0 (20.8,66.1) 59.0 (34.8,74.1) 68.8 (48.2,81.0)
60% -0.8 (-45.4,27.3) 8.6 (-30.6,36.4) 17.1 (-19.9,42.7) 30.9 (-2.2,54.4) 40.5 (10.1,60.6) 52.5 (25.0,68.7) 61.6 (39.6,76.3) 69.2 (48.0,81.6)
80% -0.4 (-46.4,26.8) 9.7 (-29.3,37.2) 18.1 (-19.8,44.1) 29.3 (-7.0,51.7) 40.5 (9.6,60.9) 48.4 (19.2,67.2) 58.7 (33.6,73.9) 69.5 (48.4,82.1)
Eˆ
Eˆ
Eˆ
Table 3: Estimates of effectiveness against HIV ( ) and 95% confidence intervals for simulated Kisumu MC trials under different levels 
of true efficacy against HIV (EH) and STI (ES) and base-case assumptions. Values for  are the median values obtained over 100 
repetitions while values in brackets are the median values for upper and lower limits of 95% confidence intervals for F.
Estimated and 
95% CI
Efficacy against HIV (true EH)
0% 10% 20% 30% 40% 50% 60% 70%
Efficacy 
against STI 
(true ES)
0% -0.9 (-43.2,27.6) 8.8 (-28.2,35.8) 20.4 (-13.7,44.0) 28.6 (-4.2,51.2) 37.5 (7.4,58.2) 49.3 (22.7,66.7) 58.0 (34.6,73.6) 69.2 (48.5,81.2)
20% 4.2 (-34.7,32.5) 12.3 (-25.3,38.1) 22.7 (-13.5,46.7) 34.8 (4.7,55.2) 40.6 (12.4,59.7) 52.8 (28.0,69.4) 61.0 (40.0,75.2) 71.7 (52.5,83.2)
40% 5.6 (-34.4,34.3) 15.2 (-17.0,42.9) 25.4 (-6.7,49.3) 33.8 (3.3,54.8) 40.9 (12.5,60.3) 51.3 (26.0,68.6) 61.6 (39.3,76.0) 70.8 (52.2,82.2)
60% 7.9 (-32.,35.3) 17.8 (-17.1,42.3) 27.1 (-5.1,49.8) 37.7 (7.2,57.7) 46.5 (20.1,64.1) 56.8 (33.2,71.6) 64.9 (44.9,78.3) 72.8 (53.5,83.4)
80% 13.3 (-24.3,38.0) 22.4 (-11.6,45.2) 28.9 (-3.0,50.9) 38.7 (7.6,58.0) 49.4 (24.0,66.0) 56.3 (32.0,72.2) 64.7 (43.8,77.6) 73.9 (56.0,84.4)
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Emerging Themes in Epidemiology 2006, 3:19 http://www.ete-online.com/content/3/1/19based on dichotomous variable representing ever having
STI during follow-up, EH was consistently underestimated
by ~5% compared to exact times. Thus even when data on
HIV and STI infection times is interval censored, efficacy
estimation is feasible, and STI infection times are prefera-
ble to 'STI-ever'. In other words, efficacy estimation using
the Anderson-Gill counting process which computes each
individual's HIV infection risk within STI-positive and
STI-negative person-time intervals is preferable to a
dichotomous STI indicator covariate. In sensitivity analy-
ses, H estimates remained within plus or minus 4% of
the true EH, though estimates were more variable when
incidence of HIV was lower in scenarios where STI preva-
lence was low or the strength of STI cofactor was weak.
Eˆ
Attributable Fraction and Effectiveness PlanesFigure 1
Attributable Fraction and Effectiveness Planes. Left Panel is attributable fraction plane showing regions of low (ligher purple) to 
high (darker purple) percentage of HIV infections prevented which are attributable in to MC efficacy against STI at different 
combinations of MC efficacy against HIV (EH) and STI (ES). Right panel is plane showing regions of low (lighter gold) to high 
(darker gold) effectiveness at different combinations of MC efficacy against HIV (EH) and STI (ES).
Efficacy against STI (ES)
E
ff
ic
a
c
y
 a
g
a
in
s
t 
H
IV
 (
E
H
)
0 – 5%
5 – 10%
20 – 30%
30 – 40%
40 – 50%
60 - 70%
80 – 90%
10 - 20%
90 - 100%
80 - 90%
60 - 70%
50 - 60%
40 - 50%
30 - 40%
20 - 30%
10 - 20%
0 – 10%
70 - 80%
Table 4: Expected efficacy estimates against STI ( S) and 95% confidence intervals for simulated Kisumu MC trials under different 
levels of true efficacy against HIV (EH) and STI (ES) and base-case assumptions. Values for S are the median values obtained over 100 
repetitions while values in brackets are the median values for upper and lower limits of 95% confidence intervals for ES.
Estimated S 
and 95% CI
Efficacy against HIV (true EH)
0% 10% 20% 30% 40% 50% 60% 70%
Efficacy 
against STI 
(true ES)
0% -0.5 (-19.1,15.2) -0.8 (-19.7,14.8) -1.2 (-18.6,15.1) -0.2 (-18.6,15.1) -2.0 (-20.4,14.2) -1.7 (-20.1,13.9) -2.0 (-20.1,13.9) -4.7 (-23.8,11.4)
20% 18.0 (2.1,31.7) 17.9 (1.5,31.2) 18.4 (2.6,31.8) 16.7 (0.6,30.5) 17.4 (1.1,30.6) 16.7 (0.6,30.6) 16.9 (0.1,30.5) 18.1 (1.9,31.4)
40% 37.5 (24.2,48.5) 36.8 (23.3,47.9) 37.0 (23.5,47.9) 38.0 (24.4,52.0) 38.0 (24.6,48.9) 36.3 (22.8,47.6) 37.9 (24.8,48.9) 37.5 (42.2,48.4)
60% 58.0 (47.9,66.3) 58.8 (48.8,66.9) 58.0 (47.8,66.2) 58.0 (47.6,66.2) 57.1 (46.7,65.5) 57.1 (46.7,65.5) 57.2 (46.7,65.5) 57.5 (47.0,65.5)
80% 78.8 (71.9,84.2) 79.3 (72.4,84.4) 78.3 (71.1,83.6) 79.2 (72.2,84.1) 78.7 (71.8,84.0) 78.8 (71.6,84.0) 78.4 (71.4,83.5) 78.2 (71.1,83.6)
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When MC efficacy against HIV is zero (true EH = 0%, true
ES > 0%; first column of Tables 2 &3), we observe that 
estimates diverge from the true efficacy value of zero as the
efficacy of circumcision against STI (ES) increases. For
example, when true ES = 40% the predicted trial effective-
ness is around 6% (  = 5.6%), while effectiveness is up
to 13% (  = 13.3%) when ES = 80%. Note however that
for all true ES values, estimates of EH remain stable around
zero ( H = -1.4 to 0.5%). In these simulations, the effec-
tiveness is due entirely to the indirect protection against
HIV achieved by MC efficacy against STI, but this can be
ascertained only by observing the H and S estimates,
which reflect their true values of EH and ES (e.g.  = 13.3%
when H = -0.4% and S = 78.8%). These results suggest
that, under our parameter assumptions, even if MC has a
very high efficacy against STI, it is unlikely to produce a
large overall HIV effectiveness if circumcision does not
also protect against HIV.
This seemingly small impact is understandable since the
reduction in HIV infections during the two year follow-up
period would, under these efficacy assumptions, be
achieved only indirectly as the prevalence of STI in cir-
cumcised men declines relative to the controls. In our sim-
ulations, the STI prevalence at recruitment averaged 8.2%
and remained constant in control subjects. However, in
circumcised men, STI prevalence declined over two years
to 2.9% when true S = 80%, as new STI infections were
substantially reduced and as prevalent infections recov-
ered with an average duration of six months.
To further explore why STIs play a small role in preventing
HIV infection, we approximate the fraction of all HIV
infections attributable to the STI in the trial. We do this by
'removing' the HIV-STI interaction effect in circumcised
men by simulating perfect efficacy against STI and zero
efficacy against HIV (ES = 100%, EH = 0%) and increasing
the follow-up period to five years. This resulted in STI
prevalence of 0.7% at five years in circumcised men and
an estimated  = 21.0%. We interpret this figure both as
the proportion of all HIV infections attributable to STI
coinfection and as the upper limit of effectiveness which
would be possible in a MC trial where MC has no protec-
tive efficacy against HIV. Our sensitivity analyses demon-
strated that this upper limit of effectiveness could be as
high as 25% to 30% under high strength of HIV-STI inter-
action effect or high STI prevalence, but these scenarios
were associated with over 10% annual HIV incidence and
would therefore not appear to be realistic for current MC
trials.
Attributable fraction
When both efficacy mechanisms combine (true EH > 0%,
true ES > 0%), the interpretation of effectiveness becomes
more complex. Different combinations of true EH and true
ES can produce similar  estimates. For example, an esti-
mated overall effectiveness  around 40% can be the
result of either true EH = 40% and ES = 0–20% or EH = 30%
and ES = 60–80% (Tables 2 &3). In general, several com-
binations of efficacies will give rise to a given effective-
ness, particularly where the intervention is neither
strongly nor weakly effective.
We also note that the greater the true ES and weaker the
true EH then the greater is the difference between  esti-
mates and true EH. For example, estimates of  are
around 22.4% when true EH = 10% and true ES = 80%
compared to  = 8.8% if true EH = 10% and ES = 0%. In
both cases, H reflected true EH ( H = 9.3% and 9.7%)
while S reflected true ES ( S = -0.8 and 79.3%). The
validity of the efficacy estimates make apparent when the
majority of HIV infections averted in the circumcised arm
of the trial were due to protection against STI, and this can
be quantified in the AF.
Figure 1 plots several values for  (calculated from the
estimated H and ), illustrating regions of equivalent
proportions of HIV infections prevented due to MC effi-
cacy against STI, as a function of true EH and ES and under
base-case parameter assumptions. The lightest purple
region indicates when  will be 0–5%, while the darkest
shows when  will be 80–90%. In general, EH must be
below 20% for a substantial proportion of HIV infections
to be prevented via STI. For example, if efficacy against
HIV and STI are 10% and 80%, respectively, then about
60% of HIV infections would be prevented in the circum-
cised arm due to MC efficacy against STI. The  declines
very quickly as EH increases. If EH is above 40%, then at
most 21% of HIV cases prevented in the circumcised arm
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Emerging Themes in Epidemiology 2006, 3:19 http://www.ete-online.com/content/3/1/19could be expected to be due to STI, even if true ES is as high
as 100%. Figure 1 also shows the regions of equivalent
effectiveness resulting from different combinations of EH
and ES in a two year MC trial. The lightest gold region
shows when total effectiveness will be 0–10%, while the
darkest indicates when  will be 90–100%. The regions
are almost horizontal, particularly at high efficacy against
HIV, suggesting that efficacy against STI will play a minor
role in overall effectiveness. Both panels of Figure 1
together illustrate that even in regions where  are high,
the overall effectiveness remains low. For example, when
EH = 15%,  may be as high as 60–70%, but  would
be unlikely be greater than 20–30%. Furthermore, it is
only in regions where  is low that high efficacy is pos-
sible for example, if true EH = 60% and true ES = 60%, then
 is 5–10% while  is 60–70%. Thus, under our base-
case parameter assumptions, a large observed effective-
ness is unlikely to be possible without a significant MC
efficacy against HIV, whatever the MC efficacy against STI.
Figure 1 also shows that a 60% effectiveness (c.f. Orange
Farm MC trial reported 61% effectiveness) could have
been the result of 60% efficacy against HIV and no efficacy
against STI, at one extreme, and 50% efficacy against HIV
combined with nearly 100% efficacy against STI, at the
other. Similarly, an effectiveness of 50% (c.f. Kisumu and
Rakai MC trials found 53% and 48% effectiveness) could
be the result of 50% efficacy against HIV and no efficacy
against STI or 39% efficacy against HIV and 100% efficacy
against STI. The corresponding  in such cases could
not be more than 10–20%. Thus, assuming similarity of
Kisumu, Orange Farm and Rakai MC trials with respect to
their design and epidemiological conditions, STI proba-
bly played a minor role in the significant effectiveness esti-
mates from the three landmark MC studies.
Simulations performed for sensitivity analyses showed
that conditions which increase STI prevalence or the
strength of STI cofactor effect increase, predictably, the AF,
but this change was only moderate. For example, when
true EH = 50% and ES = 80%, the  was 11.7% under
base-case assumptions, but  was 13.0% to 16.9%
under high STI prevalence or high strength of HIV-STI
interaction effect. Generally, the  increased by only 3%
to 11% in scenarios with the heightened role of STI com-
pared to the base-case assumptions.
Under conditions which lessen the importance of STI (i.e.
lower STI prevalence and weaker HIV-STI interaction
effect), the  varied from 3.2% to 6.6% under the same
efficacy assumptions. It was generally the case in univari-
ate and bivariate sensitivity analyses that  was not
much affected by changes in parameter assumptions,
except when true EH was very small (between 0 to 20%).
Under scenarios of lessened importance of STI,  and H
estimates generally did not differ by more than 3%. Close-
ness of H and  in these scenarios did not diminish the
relevance of efficacy estimation for both STI and HIV since
the efficacy estimates served to explain whether most of
the effectiveness was due to direct reduction of suscepti-
bility against HIV and whether the similarity between
effectiveness and efficacy is due to low ES or to weak STI-
HIV interaction.
Conclusion
Our findings have implications first for the interpretation
and analysis of circumcision trials and second for under-
standing the broader public health impact of MC. In the
context of the current male circumcision trials and under
our epidemiological assumptions, our results suggest that
the protective efficacy of MC against STI alone is unlikely
to produce large overall estimates of HIV effectiveness. For
instance, effectiveness would be estimated at less than
~20%, even if the protective effect of MC against STI is as
high as 80%. Moreover, the fraction of HIV infections
attributable to MC efficacy against STI is unlikely to be
high, except when protective efficacy of MC against HIV is
small (EH ~ 0–20%). A corollary is if a MC trial demon-
strates a moderate to high effectiveness (  ~ 40% or
more), then only a minority of HIV infections in the trial
are likely to have been prevented by protection against
STI. In other words, a moderate to high effectiveness can
be achieved only with moderate to high MC efficacy
against HIV. Thus, assuming similarity between Kisumu
and Orange Farm studies in terms of HIV and STI epide-
miology, the 61% effectiveness of MC found in the
Orange Farm study was mostly due to an efficacy against
HIV of 50–60%. Similarly, the 53% and 48% effectiveness
found in the Kisumu and Rakai studies were mostly due
to efficacy against HIV of 39% to 53%. Our sensitivity
analysis shows this is likely to be the case even with higher
STI cofactor effect and higher STI prevalence.
These conclusions on the importance of STI for HIV effec-
tiveness could be made only because estimation of the
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ble. Our results also help guide the choice of statistical
analysis and their interpretation. Estimation of F alone
may lead to equivocal interpretations as we may not know
how much an observed effectiveness was due to direct
protection against HIV or indirect protection via STI
reduction. Furthermore, the  estimate alone could not
be extrapolated to settings where prevalence and inci-
dence of the STIs in question are different from the trial
setting. However, efficacy estimates should be valid
beyond the trial setting and enhance the interpretation
and extrapolation of results. We have shown that efficacy
estimation is feasible with Anderson-Gill analyses under
realistic trial conditions. These analyses should be consid-
ered for HIV prevention trials in which the intervention
may protect against both STI and HIV. This could be the
case with female-use microbicides and diaphragms. The
same methodological issues concerning statistical efficacy
and effectiveness estimation and interpretation of results
are posed for those trials.
Public health decision makers are unlikely to be interested
in circumcision if effectiveness is low (< ~ 30%). On the
basis of our findings, the usefulness of circumcision
against HIV when effectiveness is high (> ~ 50%) may not
be questioned since a small fraction of prevented HIV
infections will be expected to be due to the indirect effect
of circumcision against STI. It could be argued that sepa-
rate estimates of efficacy against HIV and STI are most
essential when effectiveness is moderate (~30%–50%), as
public health decisions would have to give greater consid-
eration to the role of STI in the prevention of HIV with
MC. However, we argue that efficacy estimation of MC
against STI and HIV is important in all cases because effec-
tiveness estimates do not give the full picture for the
longer-term community-level impact of MC. This is for
two reasons. First, different combinations of efficacies (EH
and ES) can produce equivalent effectiveness estimates in
a trial context but not equivalent impact in a general pop-
ulation. Second, effectiveness estimated in a randomised
trial does not correspond exactly to epidemiological effec-
tiveness. In particular, the herd effect of MC benefiting
females cannot be captured by trial estimates. By sepa-
rately estimating EH and ES, transmission dynamic models
can project better the potential epidemiological impact of
MC. Further simulations with our model illustrated this
point. For example, if MC had 40% efficacy against HIV
and reached 75% of males in Kisumu, then after 10 years
a 23% decline in HIV prevalence is possible in men com-
pared to 7% in women, assuming MC does not protect
against STI. However, if MC is also efficacious against STI,
these declines in HIV prevalence are 29% for males and
14% in females, indicating the incremental benefit of STI
efficacy is larger for women than men. This is essentially
due to the fact that MC efficacy impact on male STI prev-
alence more rapidly than on HIV prevalence, and
women's exposure to STI is consequently reduced quickly.
Such insights would not be possible with effectiveness
estimates alone. Thus, in terms of evaluating the public
health potential of MC for both men and women, it will
be essential to accurately estimate both EH and ES, even if
high HIV effectiveness is observed.
Our mathematical model included only one simplistically
modelled STI. The treatment of STI in this manner can be
viewed as not one but a collection of STIs which taken
together determine STI prevalence and collectively have
an average HIV-STI interaction effect on HIV transmis-
sion. MC efficacy against these STIs can also be seen as
some mean of the efficacies against the individual STIs.
Though this is a simplified treatment of STIs, general con-
clusions on the level of importance of STIs held over a
wide range of parameter assumptions in our sensitivity
analyses.
Nevertheless, this still leaves unanswered the question of
how to deal with several categories of STIs in a trial setting
(e.g. genital ulcer disease, herpes, syphilis, chancroid,
gonorrhoea, chlamydia, etc.). At one extreme, analyses
could define STI-positive person-time on the basis of
infection with any of the above and STI-negative person-
time on basis of no STI infection of any type. At the other
extreme, one could attempt to control individually for
each of the different STIs in the statistical analyses, but
how well this may work needs to be validated. If feasible,
this would offer even greater value to the phase 3 trial by
indicating the specific categories of STIs against which cir-
cumcision is beneficial.
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Endnotes
Stochastic mathematical model
The model consists of ten disease states (h = 1,...,5 and s =
1,2) representing five different stages of HIV infection and
two states of STI infection (Figure 2). The number of indi-
viduals in the population in HIV infection state h, STI
infection state s, activity class i and of sex k at time t, is
given by (t). HIV susceptibles are labelled with the
superscript h = 1, full blown AIDS patients with h = 5, and
HIV infecteds in three stages of HIV infection (having dif-
ferent degrees of infectiousness) with h = 2,3,4. Individu-
als infected with STI are denoted by s = 1 and those not
infected with STI by s = 0. The sexually active population
is stratified by sex (k = 1 for women, k = 2 for men) and
by sexual activity class defined by the rate of sexual partner
acquisition. Six activity classes are defined (i = 1,...,6)
where at one extreme are individuals of low sexual activity
(i = 1,2) and at the other are high activity individuals (i =
3,4,5,6). Transition events between states occur by infec-
tion, progression to disease, departure from the sexually
active population or immigration into the population.
Given a stratification of two sexes and six sexual activity
classes, 336 possible events can occur (2 sexes × 6 classes
× 28 possible events) in the absence a clinical trial, as
defined in Figure 2 and Table 5.
Upon commencement of the clinical trial in the defined
population, a sample of individuals is randomized
between control and treated arms. As defined in Figure 3,
the number of controls of HIV disease state h, STI infec-
tion state s, sex k and activity class i at time t is denoted
(t). The number circumcised at time t of disease state
h, state i, sex k and activity class i is given by (t). The
number of possible events after the trial begins is 984 (2
sexes × 6 activity classes × 82 events), as given in Table 5.
In the stochastic simulations, a random sequence of indi-
vidual events is generated where each of the 984 possible
events occurs with probability  where
. The event chosen at each step of the
sequence is determined by a random number generator
according to the 984 probabilities. The time a person of
sex k and class i spends in a specific state r before making
a transition is assumed to be exponentially distributed
with mean . Furthermore, the time between any
two events is exponentially distributed with mean S-1(t).
The time of occurrence s of chosen event r can be deter-
mined by choosing a random number from a uniform dis-
tribution and setting it equal to F(s) in the equation F(s)
= 1-exp(-S(t)s) and solving for s. Thus by an iterative proc-
ess, a sequence of events and their time of occurrence is
generated. With each new event all rates including forces
of infection are automatically updated.
Key event flows in the model include force of HIV infec-
tion ( (t) and (t)) and STI infection ( (t) and
(t)). The effect of treatment is assumed to reduce these
forces of infection by an amount EffHIV and EffSTI,
respectively. The force of HIV infection for sex k and activ-
ity class i at time t in the general population and controls
is given by:
Here mk,i (t) is the annual rate of partner acquisition of
persons of sex k and class i, and  is the per partner-
ship HIV transmission probability from a person in HIV
infection phase p and sex k* and class j to opposite sex k
and class i. The term φk,i,j(t) describes the mixing matrix
elements. This is essentially the probability that an indi-
vidual of sex k and class i chooses a partner of opposite sex
k* and class j (see Desai et al [27] for more details on mix-
ing equations). NAk*,j(t) is the total sexually active popu-
lation of sex k* and class j. The term a1 is a multiplicative
factor increasing the probability of transmission of HIV
when the HIV infected partner is also infected with STI.
Thus, (t) is a function of the rate of sexual partner
change, the HIV transmission probability, HIV prevalence
and epidemiological interaction between HIV and STI.
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Emerging Themes in Epidemiology 2006, 3:19 http://www.ete-online.com/content/3/1/19The force of HIV infection in an STI infected individual is
(t) = a2 (t), where a2 is a multiplicative factor
increasing the probability of transmission of HIV when
the HIV susceptible is infected with STI. Values for the
above parameters used in the simulations are given in
Table 1.
The force of HIV infection for the circumcised group is
given by (t) = (1 - EH) (t) and (t) = (1 -
EH) (t), where EH is the reduction in susceptibility to
HIV due to circumcision.
The force of STI infection in HIV susceptibles of sex k and
class i is given by:
Here ξk*,j,i is the per partnership transmission probability
of STI from sex k* and sexual activity class j to opposite sex
k and class i. Unlike for HIV transmission probabilities,
the values for STI transmission probabilities do not
change by sexual activity class. We have chosen these val-
ues because STI transmission probabilities for bacterial
STIs are high and are less affected by number of sex acts
within a partnership. In addition, we are not trying to rep-
resent the exact biology of a given STI, and the STI needs
to reflect a number of different aetiologies. The parameter
b1 is a multiplicative factor increasing the probability of
STI transmission when the STI-positive partner is also HIV
positive. In our model we set b1 = b2 = 1.
The force of STI infection in a HIV positive individual of
sex k and class i is given by (t) = b2 (t), where b2 is
a multiplicative factor increasing the probability of STI
transmission when the STI susceptible individual is HIV
positive. The force of STI infection for the circumcised
group is given by (t) = (1 - ES) (t) and (t) = (1
- ES) (t), where ES is the reduction in susceptibility to
STI due to circumcision.
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Additional compartments for clinical trial in stochastic compartmental mathematical modelFigure 3
Additional compartments for clinical trial in stochastic compartmental mathematical model. (t) is the number of individuals 
in the control arm of the trial and (t) is the number in the treated (circumcised) arm. Circumcision acts to reduce the rate 
of HIV infection according to (t) = (1 - EH) (t) and (t) = (1 - EH) (t) and the rate of STI infection according to 
(t) = (1 - ES) (t) and (t) = (1 - ES) (t) where EH and ES are the efficacy of circumcision against HIV and STI.
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